About Bacura Therapeutics
- Bacura Therapeutics is a biotechnology company developing a next-generation cancer immunotherapy platform focused on tumor-intrinsic immunogenic cell death. Our approach reprograms how cancer cells die, enabling self-directed, immune-stimulating cell death that activates anti-tumor immunity.
- The Bacura platform supports the development of multiple therapeutic modalities, including live bacterial therapeutics and scalable, non-live biologics, across solid tumor indications.
- Bacura Therapeutics was founded by Dr. Ming Zhao, an immuno-oncology expert with over 20 years in translational cancer research. Her discovery—that bacterial-derived biology can trigger tumor-intrinsic immunogenic cell death and activate anti-tumor immunity—forms the core of Bacura’s proprietary platform.
Bacura's Platform and Pipelines
The Bacura platform is a microbial discovery and translation engine focused on reprogramming how cancer cells die. Through a phenotype-driven approach, we identify bacterial-derived biofactors that induce tumor-intrinsic, self-directed immunogenic cell death, coupled with autocrine cytokine signaling that enhances anti-tumor immunity. This platform supports both live bacterial therapeutics (BacuraVax) and non-live biologics (Bacura-SN).
BacuraVax
- Modality: Live engineered bacterial therapeutic
- Role: Platform validation and indication-specific development
- Status: Preclinical
Bacura-SN
- Modality: Non-live biologic (cell free)
- Role: Lead clinical development candidate
- Status: Preclinical / IND-enabling